Wolverine Trading’s Citius Pharmaceuticals CTXR Stock Holding History

Wolverine Trading’s Portfolio CTXR Stock Details CTXR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-437	Closed	-$19K	–	4686
2022 Q1	$19K	Buy	+437	New	+$17.3K	﹤0.01%	5251

Other funds holding CTXR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Wolverine Trading's CTXR Position: Q2 2022 in Review

Wolverine Trading sold out of Citius Pharmaceuticals (CTXR) in Q2 2022, closing a stake of 437 shares — an estimated $19K sold.

Wolverine Trading first reported a position in CTXR in Q1 2022 and held it in 1 quarter. The position peaked at $19K in Q1 2022. 60 funds tracked by Wall St. Rank hold CTXR as of Q2 2022.

Wolverine Trading reported no remaining Citius Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
Wolverine Trading sold 437 Citius Pharmaceuticals shares in Q2 2022, an estimated $19K.
Wolverine Trading first reported a position in Citius Pharmaceuticals in Q1 2022 and held it in 1 quarter.
Wolverine Trading's Citius Pharmaceuticals position peaked at $19K in Q1 2022.
60 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q2 2022.

Based on Wolverine Trading's 13F filing for Q2 2022, filed 15 Aug 2022.